148 related articles for article (PubMed ID: 21507492)
1. Vitamin D-related gene expression profiles in immune cells of patients with relapsing remitting multiple sclerosis.
Smolders J; Thewissen M; Theunissen R; Peelen E; Knippenberg S; Menheere P; Cohen Tervaert JW; Hupperts R; Damoiseaux J
J Neuroimmunol; 2011 Jun; 235(1-2):91-7. PubMed ID: 21507492
[TBL] [Abstract][Full Text] [Related]
2. Altered naive CD4 and CD8 T cell homeostasis in patients with relapsing-remitting multiple sclerosis: thymic versus peripheral (non-thymic) mechanisms.
Duszczyszyn DA; Beck JD; Antel J; Bar-Or A; Lapierre Y; Gadag V; Haegert DG
Clin Exp Immunol; 2006 Feb; 143(2):305-13. PubMed ID: 16412055
[TBL] [Abstract][Full Text] [Related]
3. Laquinimod suppress antigen presentation in relapsing-remitting multiple sclerosis: in-vitro high-throughput gene expression study.
Gurevich M; Gritzman T; Orbach R; Tuller T; Feldman A; Achiron A
J Neuroimmunol; 2010 Apr; 221(1-2):87-94. PubMed ID: 20347159
[TBL] [Abstract][Full Text] [Related]
4. Secondary progressive in contrast to relapsing-remitting multiple sclerosis patients show a normal CD4+CD25+ regulatory T-cell function and FOXP3 expression.
Venken K; Hellings N; Hensen K; Rummens JL; Medaer R; D'hooghe MB; Dubois B; Raus J; Stinissen P
J Neurosci Res; 2006 Jun; 83(8):1432-46. PubMed ID: 16583400
[TBL] [Abstract][Full Text] [Related]
5. Vitamin D-mediated immune regulation in multiple sclerosis.
Correale J; Ysrraelit MC; Gaitán MI
J Neurol Sci; 2011 Dec; 311(1-2):23-31. PubMed ID: 21723567
[TBL] [Abstract][Full Text] [Related]
6. pSTAT1, pSTAT3, and T-bet expression in peripheral blood mononuclear cells from relapsing-remitting multiple sclerosis patients correlates with disease activity.
Frisullo G; Angelucci F; Caggiula M; Nociti V; Iorio R; Patanella AK; Sancricca C; Mirabella M; Tonali PA; Batocchi AP
J Neurosci Res; 2006 Oct; 84(5):1027-36. PubMed ID: 16865709
[TBL] [Abstract][Full Text] [Related]
7. Association between peripheral IFN-gamma producing CD8+ T-cells and disability score in relapsing-remitting multiple sclerosis.
Sepulcre J; Sanchez-Ibarrola A; Moreno C; de Castro P
Cytokine; 2005 Oct; 32(2):111-6. PubMed ID: 16246570
[TBL] [Abstract][Full Text] [Related]
8. Immunomonitoring measures in relapsing-remitting multiple sclerosis.
Matsui M; Araya SI; Wang HY; Matsushima K; Saida T
J Neuroimmunol; 2004 Mar; 148(1-2):192-9. PubMed ID: 14975601
[TBL] [Abstract][Full Text] [Related]
9. Dynamic T-lymphocyte chemokine receptor expression induced by interferon-beta therapy in multiple sclerosis.
Krakauer M; Sorensen PS; Khademi M; Olsson T; Sellebjerg F
Scand J Immunol; 2006 Aug; 64(2):155-63. PubMed ID: 16867161
[TBL] [Abstract][Full Text] [Related]
10. Expansion of CD4+CD28- T cells producing high levels of interferon-{gamma} in peripheral blood of patients with multiple sclerosis.
Miyazaki Y; Iwabuchi K; Kikuchi S; Fukazawa T; Niino M; Hirotani M; Sasaki H; Onoé K
Mult Scler; 2008 Sep; 14(8):1044-55. PubMed ID: 18573819
[TBL] [Abstract][Full Text] [Related]
11. Glucocorticoid treatment reduces T-bet and pSTAT1 expression in mononuclear cells from relapsing remitting multiple sclerosis patients.
Frisullo G; Nociti V; Iorio R; Katia Patanella A; Bianco A; Caggiula M; Sancricca C; Tonali PA; Mirabella M; Batocchi AP
Clin Immunol; 2007 Sep; 124(3):284-93. PubMed ID: 17627892
[TBL] [Abstract][Full Text] [Related]
12. Effect of IFN-beta therapy on the frequency and function of CD4(+)CD25(+) regulatory T cells and Foxp3 gene expression in relapsing-remitting multiple sclerosis (RRMS): a preliminary study.
Namdar A; Nikbin B; Ghabaee M; Bayati A; Izad M
J Neuroimmunol; 2010 Jan; 218(1-2):120-4. PubMed ID: 19932513
[TBL] [Abstract][Full Text] [Related]
13. Multiple sclerosis: chemokine receptor expression on circulating lymphocytes in correlation with radiographic measures of tissue injury.
Fox RJ; Kivisakk P; Fisher E; Tucky B; Lee JC; Rudick RA; Ransohoff RM
Mult Scler; 2008 Sep; 14(8):1036-43. PubMed ID: 18701575
[TBL] [Abstract][Full Text] [Related]
14. Increase in CCR5 Delta32/Delta32 genotype in multiple sclerosis.
Pulkkinen K; Luomala M; Kuusisto H; Lehtimäki T; Saarela M; Jalonen TO; Elovaara I
Acta Neurol Scand; 2004 May; 109(5):342-7. PubMed ID: 15080861
[TBL] [Abstract][Full Text] [Related]
15. Gender differences in 1,25 dihydroxyvitamin D3 immunomodulatory effects in multiple sclerosis patients and healthy subjects.
Correale J; Ysrraelit MC; Gaitán MI
J Immunol; 2010 Oct; 185(8):4948-58. PubMed ID: 20855882
[TBL] [Abstract][Full Text] [Related]
16. Altered expression of miR-17-5p in CD4+ lymphocytes of relapsing-remitting multiple sclerosis patients.
Lindberg RL; Hoffmann F; Mehling M; Kuhle J; Kappos L
Eur J Immunol; 2010 Mar; 40(3):888-98. PubMed ID: 20148420
[TBL] [Abstract][Full Text] [Related]
17. Failure of glatiramer acetate to modify the peripheral T cell repertoire of relapsing-remitting multiple sclerosis patients.
Berthelot L; Miqueu P; Pettré S; Guillet M; Moynard J; Wiertlewski S; Lefrère F; Brouard S; Soulillou JP; Laplaud DA
Clin Immunol; 2010 Apr; 135(1):33-42. PubMed ID: 20116333
[TBL] [Abstract][Full Text] [Related]
18. Differential microRNA expression in blood in multiple sclerosis.
Søndergaard HB; Hesse D; Krakauer M; Sørensen PS; Sellebjerg F
Mult Scler; 2013 Dec; 19(14):1849-57. PubMed ID: 23773985
[TBL] [Abstract][Full Text] [Related]
19. Time-dependent cytokine deviation toward the Th2 side in Japanese multiple sclerosis patients with interferon beta-1b.
Ochi H; Feng-Jun M; Osoegawa M; Minohara M; Murai H; Taniwaki T; Kira J
J Neurol Sci; 2004 Jul; 222(1-2):65-73. PubMed ID: 15240198
[TBL] [Abstract][Full Text] [Related]
20. Immune cell NT-3 expression is associated with brain atrophy in multiple sclerosis patients.
Kalinowska-Łyszczarz A; Pawlak MA; Michalak S; Paprzycki W; Losy J
J Neuroimmunol; 2011 Dec; 240-241():109-13. PubMed ID: 22036954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
